ACRS 8-K: Fda rejection
Aclaris Therapeutics
Filed with the SEC on · accession 0001104659-26-127478
ACRS filed a 8-K (current report) with the SEC on Nov 16, 2026. Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis failed to achieve its primary endpoint of percent change in EASI score at Week 24 or secondary endpoints, despite robust target engagement. The stock moved -8.0% by the first close after the filing.
Summary of the filing
Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis failed to achieve its primary endpoint of percent change in EASI score at Week 24 or secondary endpoints, despite robust target engagement. The company also announced initiation of a Phase 2b ALPHA trial of modzatinib in lichen planus and other pipeline updates.
Key details
How ACRS stock reacted
Close before
$3.92
Nov 13, 2026
First close after
-8.04%
$3.60
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ACRS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ACRS?
Click hereFrequently asked questions
What did ACRS file with the SEC on Nov 16, 2026?
ACRS filed a 8-K (Fda rejection). Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis failed to achieve its primary endpoint of percent change in EASI score at Week 24 or secondary endpoints, despite robust target engagement. The company also announced initiation of a Phase 2b ALPHA trial of modzatinib in lichen planus and other pipeline updates.
What does a fda rejection mean for ACRS stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did ACRS stock react to this filing?
ACRS closed at $3.92 before the filing and $3.60 on Nov 16, 2026 (-8.04%).
Other ACRS SEC filings
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- 8-K · SEC filingNov 5, 2026
- 10-Q · SEC filingNov 5, 2026
- 424B5 · Secondary offeringOct 27, 2026
- 8-K · Fda approvalOct 27, 2026
- 8-K · SEC filingOct 27, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 8-K · Material agreementAug 6, 2026
- 8-K · SEC filingAug 6, 2026
- 10-Q · SEC filingAug 6, 2026
Get alerts when ACRS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days